Aminohippuric Acid
drugOn this page
Also known as p-NSC-13064P-aminohippuric acidPara-aminohippurateSID11112164SID26748682SID56463545SID124882008SID144203896[3H]para-amino-hippuric acidSID170465155AminohippurateP-amino-hippuric acidAMINOHIPPURIC_acid
Summary
Aminohippuric Acid (CHEMBL463) is an approved small molecule (ATC V04CH30).
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: V04CH30
- Clinical trials: 14
- Chemistry: 194.19 Da · C9H10N2O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL463 |
| Name | Aminohippuric Acid |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 2148 |
| ChEBI | CHEBI:104011 |
| ATC | V04CH30 |
| Molecular formula | C9H10N2O3 |
| Molecular weight | 194.19 |
| InChIKey | HSMNQINEKMPTIC-UHFFFAOYSA-N |
SMILES: C1=CC(=CC=C1C(=O)NCC(=O)O)N
IUPAC name: 2-[(4-aminobenzoyl)amino]acetic acid
ChEBI definition: An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.
Other ChEBI roles (chemical / environmental): Daphnia magna metabolite.
Also known as: Aminohippuric acid, p-, NSC-13064, P-aminohippuric acid, Para-aminohippurate, SID11112164, SID26748682, SID56463545, para-aminohippurate, p-Aminohippuric acid, p-aminohippuric acid, P-Aminohippuric acid
Parent form; salt/anhydrous children: CHEMBL1200365
Patent coverage: 670 distinct patent families (2,260 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Solute carrier family 22 member 6, Organic anion transporter 3, Beta-lactamase, Hypoxia-inducible factor 1-alpha, Solute carrier family 22 member 6.
Bioactivity
ChEMBL activities: 8 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| HIF1A | 5.3 | Potency | 5012 | nM | CHEMBL_ACT_4125909 |
| HIF1A | 5.3 | Potency | 5012 | nM | CHEMBL_ACT_4520118 |
| P00811 | 5.25 | Potency | 5623 | nM | CHEMBL_ACT_4668436 |
| SLC22A6 | 5.22 | Ki | 6020 | nM | CHEMBL_ACT_11003209 |
| SLC22A6 | 5.22 | Ki | 6020 | nM | CHEMBL_ACT_6204571 |
| SLC22A6 | 5.06 | IC50 | 8800 | nM | CHEMBL_ACT_11001874 |
| Q8VC69 | 5.03 | Ki | 9333 | nM | CHEMBL_ACT_2182620 |
| Q8VC69 | 5.03 | Ki | 9400 | nM | CHEMBL_ACT_2182621 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 14.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE1/PHASE2 | 3 |
| PHASE4 | 2 |
| PHASE1 | 2 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04113109 | PHASE4 | COMPLETED | Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 |
| NCT04649229 | PHASE4 | COMPLETED | Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 |
| NCT05507892 | PHASE2 | RECRUITING | Renal Mechanism of SGLT2 Inhibition |
| NCT03584217 | PHASE1/PHASE2 | UNKNOWN | Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study |
| NCT03618420 | PHASE1/PHASE2 | COMPLETED | Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function |
| NCT03620773 | PHASE1/PHASE2 | COMPLETED | Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes |
| NCT05065372 | PHASE1 | RECRUITING | MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes |
| NCT01214993 | PHASE1 | COMPLETED | A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects |
| NCT05008276 | Not specified | RECRUITING | Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study) |
| NCT05319990 | Not specified | ACTIVE_NOT_RECRUITING | Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study) |
| NCT05530356 | Not specified | ENROLLING_BY_INVITATION | Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study |
| NCT05694624 | Not specified | RECRUITING | Investigations Into Sepsis-associated Acute Kidney Injury |
| NCT04074668 | Not specified | COMPLETED | Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance |
| NCT04407481 | Not specified | COMPLETED | PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.